EGFR (T790M/L792F/L858R)
Sign in to save this workspaceEGFR · Variant type: compound · HGVS: p.T790M;p.L792F;p.L858R
Components
p.T790Mp.L792Fp.L858R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Canertinib | 99.5% | 0.5% | 96.49 |
| 2 | Lazertinib | 98.6% | 1.4% | 97.47 |
| 3 | Mobocertinib | 98.5% | 1.5% | 97.22 |
| 4 | Osimertinib | 97.3% | 2.7% | 97.24 |
| 5 | Dacomitinib | 97.0% | 3.0% | 97.99 |
| 6 | Fostamatinib | 94.7% | 5.3% | 96.74 |
| 7 | Pacritinib | 93.0% | 7.0% | 88.64 |
| 8 | Brigatinib | 91.8% | 8.2% | 82.96 |
| 9 | Capmatinib | 90.6% | 9.4% | 99.75 |
| 10 | Neratinib | 84.9% | 15.1% | 93.18 |
| 11 | Gilteritinib | 75.8% | 24.2% | 88.97 |
| 12 | Deucravacitinib | 75.6% | 24.4% | 98.99 |
| 13 | Ibrutinib | 63.5% | 36.5% | 94.74 |
| 14 | Pralsetinib | 58.9% | 41.1% | 93.43 |
| 15 | Sunitinib | 40.3% | 59.7% | 91.73 |
| 16 | Vandetanib | 38.1% | 61.9% | 95.74 |
| 17 | Pazopanib | 36.8% | 63.2% | 97.49 |
| 18 | Defactinib | 34.5% | 65.5% | 92.68 |
| 19 | Entrectinib | 31.2% | 68.8% | 93.69 |
| 20 | Erlotinib | 27.7% | 72.3% | 99.75 |
| 21 | Fedratinib | 24.8% | 75.2% | 96.21 |
| 22 | Alectinib | 19.7% | 80.3% | 95.49 |
| 23 | Lapatinib | 19.1% | 80.9% | 99.25 |
| 24 | Tofacitinib | 18.7% | 81.3% | 99.25 |
| 25 | Avapritinib | 17.9% | 82.1% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Canertinib | 99.5% | 98.4% | +1.1% |
| Lazertinib | 98.6% | 100.0% | -1.4% |
| Mobocertinib | 98.5% | 100.0% | -1.5% |
| Osimertinib | 97.3% | 99.1% | -1.8% |
| Dacomitinib | 97.0% | 99.8% | -2.8% |
| Fostamatinib | 94.7% | 97.8% | -3.1% |
| Pacritinib | 93.0% | — | — |
| Brigatinib | 91.8% | 98.5% | -6.6% |
| Capmatinib | 90.6% | — | — |
| Neratinib | 84.9% | 100.0% | -15.1% |
| Gilteritinib | 75.8% | 91.0% | -15.2% |
| Deucravacitinib | 75.6% | — | — |
| Ibrutinib | 63.5% | 99.3% | -35.9% |
| Pralsetinib | 58.9% | 99.1% | -40.2% |
| Sunitinib | 40.3% | — | — |
| Vandetanib | 38.1% | 99.3% | -61.2% |
| Pazopanib | 36.8% | — | — |
| Defactinib | 34.5% | 94.6% | -60.1% |
| Entrectinib | 31.2% | — | — |
| Erlotinib | 27.7% | 99.4% | -71.7% |
| Fedratinib | 24.8% | — | — |
| Alectinib | 19.7% | — | — |
| Lapatinib | 19.1% | 99.2% | -80.1% |
| Tofacitinib | 18.7% | — | — |
| Avapritinib | 17.9% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 17.2ms